Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

医学 比索洛尔 心绞痛 β受体阻滞剂 心力衰竭 心脏病学 心肌梗塞 血压 重症监护医学 疾病 内科学 原发性高血压
作者
Giuseppe Mancia,Sverre E. Kjeldsen,Reinhold Kreutz,Atul Pathak,Guıdo Grassı,Murray Esler
出处
期刊:Hypertension [Ovid Technologies (Wolters Kluwer)]
卷期号:79 (6): 1153-1166 被引量:49
标识
DOI:10.1161/hypertensionaha.122.19020
摘要

Several hypertension guidelines have removed beta-blockers from their previous position as first-choice drugs for the treatment of hypertension. However, this downgrading may not be justified by available evidence because beta-blockers lower blood pressure as effectively as other major antihypertensive drugs and have solid documentation in preventing cardiovascular complications. Suspected inconveniences of beta-blockers such as increased risk of depression or erectile dysfunction may have been overemphasized, while patients with chronic obstructive pulmonary disease or peripheral artery disease, that is, conditions in which their use was previously restricted, will benefit from beta-blocker therapy. Besides, evidence that from early to late phases, hypertension is accompanied by activation of the sympathetic nervous system makes beta-blockers pathophysiologically an appropriate treatment in hypertension. Beta-blockers have favorable effects on a variety of clinical conditions that may coexist with hypertension, making their use either as specific treatment or as co-treatment potentially common in clinical practice. Guidelines typically limit recommendations on specific beta-blocker use to cardiac conditions including angina pectoris, postmyocardial infarction, or heart failure, with little or no mention of the additional cardiovascular or noncardiovascular conditions in which these drugs may be needed or preferred. In the present narrative review, we focus on multiple additional diseases and conditions that may occur and affect patients with hypertension, often more frequently than people without hypertension, and that may favor the choice of beta-blocker. Notwithstanding, beta-blockers represent an in-homogenous group of drugs and choosing beta-blockers with documented effect in prevention and treatment of disease is important for first choice in guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安静严青发布了新的文献求助10
刚刚
落寞怜雪发布了新的文献求助20
1秒前
47发布了新的文献求助10
2秒前
haidayu发布了新的文献求助10
2秒前
义气的一德完成签到,获得积分10
3秒前
_u_ii应助Poik采纳,获得10
3秒前
在水一方应助人木采纳,获得10
4秒前
YEM完成签到,获得积分10
5秒前
小蘑菇应助安静严青采纳,获得10
5秒前
6秒前
Sssmmmyy发布了新的文献求助10
6秒前
深情安青应助wangyue1995采纳,获得10
6秒前
麻薯太好吃了完成签到,获得积分20
7秒前
zyy完成签到,获得积分10
7秒前
淡淡白枫完成签到,获得积分10
7秒前
万能图书馆应助sometimes采纳,获得10
9秒前
9秒前
10秒前
善学以致用应助wangli采纳,获得10
11秒前
11秒前
枯叶蝶发布了新的文献求助10
12秒前
47完成签到,获得积分10
12秒前
好吃的蛋挞完成签到,获得积分10
14秒前
haidayu完成签到,获得积分10
14秒前
YuGe完成签到,获得积分10
14秒前
彭于晏应助tang采纳,获得10
15秒前
16秒前
嘉心糖应助ddd采纳,获得30
17秒前
18秒前
19秒前
20秒前
莹cy完成签到 ,获得积分10
22秒前
23秒前
library2025应助冷酷的柜门采纳,获得10
24秒前
Lucas应助Y123采纳,获得10
25秒前
Akim应助guoxihan采纳,获得10
26秒前
Yang发布了新的文献求助10
26秒前
111完成签到,获得积分10
27秒前
情怀应助柔弱亦寒采纳,获得10
28秒前
田様应助鹏哥爱科研采纳,获得10
29秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Effect of reactor temperature on FCC yield 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1020
Cognitive Paradigms in Knowledge Organisation 1000
Near Infrared Spectra of Origin-defined and Real-world Textiles (NIR-SORT): A spectroscopic and materials characterization dataset for known provenance and post-consumer fabrics 610
Mission to Mao: Us Intelligence and the Chinese Communists in World War II 600
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3306895
求助须知:如何正确求助?哪些是违规求助? 2940756
关于积分的说明 8498339
捐赠科研通 2614923
什么是DOI,文献DOI怎么找? 1428599
科研通“疑难数据库(出版商)”最低求助积分说明 663445
邀请新用户注册赠送积分活动 648297